CG Oncology (CGON) has filed to lift roughly $100M via an preliminary public providing.
The biotech firm didn’t specify any phrases in its SEC submitting, however indicated in a submitting charge schedule that it was fascinated about elevating round $100M, a quantity that is probably going a placeholder and topic to vary.
CG Oncology hopes to record its shares on Nasdaq below the image CGON. Underwriters embody Morgan Stanley, Goldman Sachs, Cantor and LifeSci Capital.
Based mostly in California, CG Oncology has been creating a bladder-sparing remedy for sufferers with bladder most cancers. The corporate’s lead drug candidate, cretostimogene, is in Part 3 testing.